Tendly Chat - AI Procurement Intelligence

Conclusion of non-exclusive drug discount agreements according to § 130a Abs. 8 SGB V using an open-house model for the active ingredient Ticagrelor (WHO ATC code: B01AC24)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Ref T-78672136·via Bekanntmachungsservice

VALUE

--

DEADLINE

Sep 30, 2026

TIME LEFT

37 days

Open-House Discount Contracts 2024-10

Techniker Krankenkasse·Ref T-1389111221·via Bekanntmachungsservice

VALUE

--

DEADLINE

Sep 30, 2026

TIME LEFT

37 days

Replacement procurement of 2 steam sterilizers (12 STE) for the LA-Regio Clinics, Klinik Landshut-Mitte

LA-Regio Kliniken Anstalt des öffentlichen Rechts der Stadt und des Landkreises Landshut·Ref T-260804688·via Bekanntmachungsservice

VALUE

--

DEADLINE

Sep 30, 2026

TIME LEFT

37 days

Open-House-Biologika-Discount-Contracts 2025-25 - Aflibercept (ATC: S01LA05; Strength: 40 mg/ml)

Techniker Krankenkasse·Ref T-756891869·via Bekanntmachungsservice

VALUE

--

DEADLINE

Nov 30, 2026

TIME LEFT

98 days

Open House Original Discount Contracts 2025-05 - Emtricitabine/Tenofovir disoproxil/Rilpivirine (drug combination)

Techniker Krankenkasse·Ref T-298730733·via Bekanntmachungsservice

VALUE

--

DEADLINE

Nov 30, 2026

TIME LEFT

98 days

Conclusion of a non-exclusive discount agreement according to § 130a para. 8 SGB V for the active ingredient Bimekizumab, ATC L04AC21 for the period 01.10.2026 - 31.03.2027

DAK-Gesundheit·Ref T-1443689617·via Bekanntmachungsservice

VALUE

€1

DEADLINE

Feb 5, 2027

TIME LEFT

165 days

Open-house drug discount agreements according to § 130a para. 8c SGB V for the KV region Brandenburg

AOK Nordost. Die Gesundheitskasse.·Ref T-807951360·via Bekanntmachungsservice

VALUE

--

DEADLINE

Feb 21, 2027

TIME LEFT

181 days

Open-house drug discount agreements according to § 130a para. 8c SGB V for the KV region Mecklenburg-Vorpommern

AOK Nordost. Die Gesundheitskasse.·Ref T-945347902·via Bekanntmachungsservice

VALUE

--

DEADLINE

Feb 21, 2027

TIME LEFT

181 days

Open-house drug discount agreements according to § 130a para. 8c SGB V for the KV region Berlin

AOK Nordost. Die Gesundheitskasse.·Ref T-104697664·via Bekanntmachungsservice

VALUE

--

DEADLINE

Feb 21, 2027

TIME LEFT

181 days

Open-house discount agreements 2025-01

Techniker Krankenkasse·Ref T-2091310200·via Bekanntmachungsservice

VALUE

--

DEADLINE

Feb 28, 2027

TIME LEFT

188 days

Conclusion not excl. drug rebate agreements according to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Oxycodone/Naloxone (WHO ATC code: N02AA55)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Ref T-1384841192·via Bekanntmachungsservice

VALUE

--

DEADLINE

Mar 31, 2027

TIME LEFT

219 days

Open House Discount Contracts 2025-02

Techniker Krankenkasse·Ref T-63199494·via Bekanntmachungsservice

VALUE

--

DEADLINE

Mar 31, 2027

TIME LEFT

219 days

Conclusion of non-exclusive drug rebate agreements according to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Denosumab Prolia (WHO ATC code: M05BX04)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Ref T-1154409128·via Bekanntmachungsservice

VALUE

--

DEADLINE

May 31, 2027

TIME LEFT

280 days

Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V using an open-house model for the active ingredient Liraglutide (ATC code according to WHO: A10BJ02; official ATC: A10BJ02)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Ref T-233374321·via Bekanntmachungsservice

VALUE

--

DEADLINE

Jun 30, 2027

TIME LEFT

310 days

Open House Biologika Discount Agreements 2026 - 15 Ranibizumab

Techniker Krankenkasse·Ref T-415107564·via Bekanntmachungsservice

VALUE

--

DEADLINE

Jun 30, 2027

TIME LEFT

310 days

Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V using an open-house model for the active ingredients Formoterol/Aclidinium bromide (ATC code according to WHO: R03AL05)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Ref T-1085737393·via Bekanntmachungsservice

VALUE

--

DEADLINE

Jun 30, 2027

TIME LEFT

310 days

Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V using an open-house model for the active ingredient Nilotinib (ATC code according to WHO: L01EA03)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Ref T-978534921·via Bekanntmachungsservice

VALUE

--

DEADLINE

Jul 31, 2027

TIME LEFT

341 days

Conclusion of a non-exclusive discount agreement according to § 130a para. 8 SGB V for medicines with the active ingredient Denosumab Xgeva (WHO ATC code: M05BX04)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Ref T-1065400148·via Bekanntmachungsservice

VALUE

--

DEADLINE

Jul 31, 2027

TIME LEFT

341 days

Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V using an open-house model for the active ingredient Ustekinumab (ATC code according to WHO: L04AC05)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Ref T-1302330612·via Bekanntmachungsservice

VALUE

--

DEADLINE

Jul 31, 2027

TIME LEFT

341 days

Open House Biologics Discount Contracts 2026-21 - Golimumab

Techniker Krankenkasse·Ref T-1745645260·via Bekanntmachungsservice

VALUE

--

DEADLINE

Jul 31, 2027

TIME LEFT

341 days

Open House Biologika Discount Contracts 2026-22 - Ustekinumab

Techniker Krankenkasse·Ref T-543823608·via Bekanntmachungsservice

VALUE

--

DEADLINE

Jul 31, 2027

TIME LEFT

341 days

Open House Biologika Discount Contracts 2026-24 - Aflibercept (ATC: S01LA05; Strength: 40 mg/ml)

Techniker Krankenkasse·Ref T-1522397085·via Bekanntmachungsservice

VALUE

--

DEADLINE

Jul 31, 2027

TIME LEFT

341 days

Conclusion of a non-exclusive discount agreement according to § 130a para. 8 or § 130c para. 8 SGB V for patent-protected active ingredients - VV93

GWQ ServicePlus AG·Ref T-57493131·via Bekanntmachungsservice

VALUE

--

DEADLINE

Aug 10, 2027

TIME LEFT

351 days

Conclusion of non-exclusive discount agreement according to § 130a Abs. 8 SGB V for patented active ingredients - VV90

GWQ ServicePlus AG·Ref T-417981358·via Bekanntmachungsservice

VALUE

--

DEADLINE

Aug 10, 2027

TIME LEFT

351 days

Medical Equipment

Medical Equipment

Conclusion of non-exclusive drug discount agreements according to § 130a Abs. 8 SGB V using an open-house model for the active ingredient Ticagrelor (WHO ATC code: B01AC24)

Open-House Discount Contracts 2024-10

Replacement procurement of 2 steam sterilizers (12 STE) for the LA-Regio Clinics, Klinik Landshut-Mitte

Open-House-Biologika-Discount-Contracts 2025-25 - Aflibercept (ATC: S01LA05; Strength: 40 mg/ml)

Open House Original Discount Contracts 2025-05 - Emtricitabine/Tenofovir disoproxil/Rilpivirine (drug combination)

Conclusion of a non-exclusive discount agreement according to § 130a para. 8 SGB V for the active ingredient Bimekizumab, ATC L04AC21 for the period 01.10.2026 - 31.03.2027

Open-house drug discount agreements according to § 130a para. 8c SGB V for the KV region Brandenburg

Open-house drug discount agreements according to § 130a para. 8c SGB V for the KV region Mecklenburg-Vorpommern

Open-house drug discount agreements according to § 130a para. 8c SGB V for the KV region Berlin

Open-house discount agreements 2025-01

Conclusion not excl. drug rebate agreements according to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Oxycodone/Naloxone (WHO ATC code: N02AA55)

Open House Discount Contracts 2025-02

Conclusion of non-exclusive drug rebate agreements according to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Denosumab Prolia (WHO ATC code: M05BX04)

Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V using an open-house model for the active ingredient Liraglutide (ATC code according to WHO: A10BJ02; official ATC: A10BJ02)

Open House Biologika Discount Agreements 2026 - 15 Ranibizumab

Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V using an open-house model for the active ingredients Formoterol/Aclidinium bromide (ATC code according to WHO: R03AL05)

Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V using an open-house model for the active ingredient Nilotinib (ATC code according to WHO: L01EA03)

Conclusion of a non-exclusive discount agreement according to § 130a para. 8 SGB V for medicines with the active ingredient Denosumab Xgeva (WHO ATC code: M05BX04)

Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V using an open-house model for the active ingredient Ustekinumab (ATC code according to WHO: L04AC05)

Open House Biologics Discount Contracts 2026-21 - Golimumab

Open House Biologika Discount Contracts 2026-22 - Ustekinumab

Open House Biologika Discount Contracts 2026-24 - Aflibercept (ATC: S01LA05; Strength: 40 mg/ml)

Conclusion of a non-exclusive discount agreement according to § 130a para. 8 or § 130c para. 8 SGB V for patent-protected active ingredients - VV93

Conclusion of non-exclusive discount agreement according to § 130a Abs. 8 SGB V for patented active ingredients - VV90